Welcome to our dedicated page for Pelthos Therapeutics news (Ticker: PTHS), a resource for investors and traders seeking the latest updates and insights on Pelthos Therapeutics stock.
Pelthos Therapeutics Inc. (PTHS) generates news primarily around its commercial dermatology portfolio and corporate development activities. As a biopharmaceutical company focused on therapeutic products for unmet patient needs, much of its coverage relates to the launch and market uptake of ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved at-home treatment for molluscum contagiosum in adults and pediatric patients one year of age and older.
Investors following Pelthos can expect regular updates on product commercialization milestones, including prescription trends, prescriber adoption, and payer access for ZELSUVMI. Company press releases have highlighted commercial agreements with pharmacy benefit managers and group purchasing organizations that expand formulary coverage and patient access, as well as educational initiatives such as the Moms Against Molluscum movement aimed at caregivers managing molluscum contagiosum.
News flow also covers portfolio expansion. Pelthos has announced acquisitions of Xepi (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, and Xeglyze (abametapir), an FDA-approved topical treatment for head lice infestation. These transactions, together with planned product relaunch timelines, feature prominently in company communications as Pelthos builds a broader cutaneous infectious disease franchise.
On the corporate and financial side, Pelthos issues releases on quarterly financial results, private financings, and credit facilities. Examples include senior secured convertible notes with investors including Ligand Pharmaceuticals and a senior secured term loan facility with Horizon Technology Finance Corporation, both described as supporting commercialization of ZELSUVMI and the integration of additional products. Governance and investor relations updates, such as board appointments and participation in healthcare and investor conferences, also appear in the company’s news stream.
For readers and investors, the Pelthos news page offers a consolidated view of these developments, providing context on how the company is executing its strategy in molluscum contagiosum, impetigo, and head lice, and how financing and partnerships are aligned with its commercial objectives.
Pelthos Therapeutics (NYSE American: PTHS) will report first quarter 2026 financial results on Thursday, May 14, 2026 and hold a conference call at 8:30 a.m. Eastern Time. The call includes a Q&A and will be accessible by phone (Conf. ID 13760399) and live webcast.
Dial-in numbers and the webcast link are provided for investor access.
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will attend one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors should contact their Piper Sandler representative to arrange meetings.
Pelthos Therapeutics (NYSE American: PTHS) appointed John M. Gay as Chief Financial Officer effective April 10, 2026. Mr. Gay, previously Senior Vice President, Finance & Accounting since 2025, brings more than 25 years of public company finance and accounting experience.
He succeeds Francis Knuettel II, who served as CFO since July 2025. Management thanked the outgoing CFO for contributions tied to the merger with Channel Therapeutics and two recent significant capital raises.
Pelthos Therapeutics (NYSE American: PTHS) announced the first patient has been dosed in a placebo-controlled Phase 1b/2a trial of CT2000, an ophthalmic NaV1.7 inhibitor for acute and chronic eye pain. The adaptive study includes ascending-dose Phase 1 and a 28-day Phase 2a MTD period. Results are anticipated by end of 2026. Channel, a Pelthos subsidiary, reported meeting predefined preclinical endpoints for CT2000 in May 2025. The company notes a global chronic ocular pain market estimate of $5.3 billion by 2032.
Pelthos Therapeutics (NYSE: PTHS) reported strong early commercial traction for ZELSUVMI, with $9.1M net product revenue in Q4 2025 and $16.2M total net sales from launch through Dec 31, 2025. Units dispensed reached 8,948 with a 129% QoQ increase in Q4. The company closed an $18M convertible note financing, drew $30M of a $50M term loan, and completed acquisitions of XEPI and XEGLYZE.
Cash was $18.0M as of Dec 31, 2025; Q4 operating loss improved to $12.0M and adjusted EBITDA loss narrowed ~22% QoQ.
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will speak in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. PT. A live webcast will be available on the company investor site and replayed for 90 days.
Pelthos Therapeutics (NYSE American: PTHS) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. A conference call and Q&A will be held at 8:00 a.m. Eastern Time the same day.
Investors can join via toll-free dial-in, international number, conference ID 13758894, or a live webcast at the provided URL.
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 10:00 a.m. ET.
The company will host one-on-one investor meetings via Oppenheimer representatives. A live webcast is available and a replay will be posted on the Pelthos investor website for 90 days after the presentation.
Pelthos Therapeutics (NYSE American: PTHS) secured a senior secured term loan facility with Horizon Technology Finance providing $30 million funded at closing and up to $20 million more (total facility up to $50 million) to support commercialization of ZELSUVMI (berdazimer) 10.3% gel, the launches of Xepi and Xeglyze, and working capital.
The loan rate is Prime + 3.75% (10.50% currently), thirty-six month amortization start (may begin month 48 if milestones met), 60-month term, and interest-only until amortization. Pelthos issued warrants for 65,488 shares at an exercise price of $27.49. Cash as of Sept 30, 2025 was $14.2 million, and the company issued $18.0 million of convertible notes on Nov 6, 2025.
Pelthos Therapeutics (NYSE American: PTHS) acquired Xeglyze (abametapir) from Hatchtech for $1.8 million on Jan 5, 2026.
Xeglyze is an FDA-approved prescription topical treatment for head lice in patients 6 months and older (approved July 2020). Pelthos obtained worldwide commercialization rights with no future milestone, royalty, or other payments owed to Hatchtech. The company plans to relaunch Xeglyze in the first half of 2027. The release cites an estimated 6–12 million annual U.S. head-lice infestations among children ages 3–11 as the addressable market context.